LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Britain Courts Anthropic Amid US Defense Department Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
BRIDGEWATER, N.J., Nov. 23, 2016 -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that John Timberlake, President and Chief Executive Officer and Erick Lucera, Chief Financial Officer are scheduled to present at two investor conferences in December 2016.
| Event: | The Benchmark Company Micro Cap Discovery One-on-One Conference | |||||||
| Format: | One-on-One Meetings | |||||||
| Date: | Thursday, December 1, 2016 | |||||||
| Location: | Chicago, IL | |||||||
| Event: | LD Micro Main Event | |||||||
| Format: | Presentation and One-on-One Meetings | |||||||
| Date: | Wednesday, December 7, 2016 | |||||||
| Time: | 9:30 a.m. PST | |||||||
| Location: | Bel Air, CA | |||||||
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas’ flagship product, V-Go® Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Christopher Hippolyte The Ruth Group (646)536-7023 [email protected]
